Denosumab new breast cancer drug in phase 3 of study
Wednesday, July 8th, 2009Denosumab Demonstrates Superiority Over Zometa(R) In Pivotal Phase 3 Head-to-Head Trial In Breast Cancer Patients With Bone Metastases.
“We are extremely pleased with the outcome of this important study, which shows that denosumab can reduce or delay the serious complications of bone metastases in breast cancer patients better than the current standard of care, and with a favorable benefit/risk profile,” said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. “These results underscore the importance of the RANK Ligand pathway in bone disease, and offer the promise of improved care for patients with advanced breast cancer. We look forward to reviewing the results from a second Phase 3 study of denosumab effects in advanced cancer patients later this year.”
from medicalnewstoday.com
Read the rest of the article



